Evaluation of Trilaciclib’s Efficacy and Safety in mTNBC Patients: Insights from the Phase 3 PRESERVE 2 Trial’
Metastatic Triple Negative Breast Cancer (mTNBC) represents a substantial medical challenge due to its aggressive nature and limited treatment options. Chemotherapy remains a cornerstone of mTNBC treatment, despite significant associated morbidity. To mitigate the adverse effects of chemotherapy, the use of Trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, has been investigated. This article provides an summary of the recent update from G1 Therapeutics on the Phase 3 PRESERVE 2 trial examining Trilaciclib’s efficacy and safety in patients with mTNBC receiving first-line chemotherapy.
Study Design and Methodology’
The Phase 3 PRESERVE 2 trial is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Trilaciclib administered prior to chemotherapy. The trial enrolled patients diagnosed with mTNBC who were receiving first-line chemotherapy. Participants were randomized to receive either Trilaciclib or placebo in conjunction with standard chemotherapy regimens.
The primary endpoint of the trial was the proportion of patients experiencing chemotherapy-induced myelosuppression, measured by the need for granulocyte colony-stimulating factor (G-CSF) support, red blood cell transfusions, and anemia-related dose reductions. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the incidence of severe neutropenia.
Preliminary Results and Findings’
The initial data from the PRESERVE 2 trial indicated that Trilaciclib administration prior to chemotherapy was associated with a statistically significant reduction in the frequency and severity of chemotherapy-induced myelosuppression. Fewer patients in the Trilaciclib cohort required G-CSF support or red blood cell transfusions compared to the placebo group. Moreover, the incidence of severe neutropenia was notably lower in the Trilaciclib group.
Preliminary analysis of secondary endpoints suggested an improvement in PFS and OS among patients receiving Trilaciclib, although these results did not reach statistical significance at this stage. The safety profile of Trilaciclib was consistent with previous studies, with most adverse events being manageable and predominantly of mild to moderate severity.
Conclusion and Future Directions’
The update from G1 Therapeutics on the Phase 3 PRESERVE 2 trial provides promising evidence supporting the use of Trilaciclib in reducing the adverse hematologic effects associated with chemotherapy in mTNBC patients. While the primary endpoint data are encouraging, further analysis is needed to confirm the potential survival benefits and fully delineate the safety profile of Trilaciclib.
Continued follow-up and future trials are necessary to establish the long-term benefits of Trilaciclib and possibly extend its use to other chemotherapy regimens and cancer types. The data from PRESERVE 2 contribute to an evolving landscape of supportive care strategies aimed at improving the quality of life and outcomes for cancer patients undergoing chemotherapy.
Title’
Trilaciclib Shows Promise in Mitigating Chemotherapy-Induced Myelosuppression in mTNBC: Insights from the Phase 3 PRESERVE 2 Trial’
Comments